About Devyser
Devyser is a company based in Stockholm (Sweden) founded in 2004. Devyser has raised $15.48 million across 2 funding rounds from investors including Swedbank Robur and Fjarde AP-fonden. The company has 132 employees as of December 31, 2024. Devyser has completed 1 acquisition, including SmartSeq. Devyser offers products and services including Devyser BRCA NGS, Devyser Chimerism NGS, Devyser Thalassemia NGS, and Devyser RHD. Devyser operates in a competitive market with competitors including Abcam, ArcherDX, Stem Cell Technologies, GenScript and Sino Biological, among others.
- Headquarter Stockholm, Sweden
- Employees 132 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Devyser Diagnostics Ab
-
Annual Revenue
$19.66 M (USD)28.12as on Dec 31, 2024
-
Net Profit
-$5.58 M (USD)-14.74as on Dec 31, 2024
-
EBITDA
-$3.68 M (USD)13.06as on Dec 31, 2024
-
Total Equity Funding
$15.48 M (USD)
in 2 rounds
-
Latest Funding Round
$15.48 M (USD), Series B
Feb 02, 2021
-
Investors
Swedbank Robur
& 1 more
-
Employee Count
132
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Devyser
Devyser is a publicly listed company on the OMXSTO with ticker symbol DVYSR in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Devyser
Devyser offers a comprehensive portfolio of products and services, including Devyser BRCA NGS, Devyser Chimerism NGS, Devyser Thalassemia NGS, and Devyser RHD.
Detects mutations in BRCA1 and BRCA2 for cancer diagnostics
Monitors chimerism in transplant patients accurately
Performs comprehensive testing for thalassemia disorders
Screens for fetal RHD in non-invasive prenatal testing
People of Devyser
Unlock access to complete
Funding Insights of Devyser
Devyser has successfully raised a total of $15.48M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15.48 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Devyser
Devyser has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Swedbank Robur and Fjarde AP-fonden.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Swedbank Robur is recognized as Sweden's largest fund management company.
|
Locked | Locked | Locked | |
|
Manages Swedish national pension assets with sustainable investment strategies.
|
Locked | Locked | Locked |
Investor details for Devyser
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Devyser
Devyser has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SmartSeq.
Investment portfolio details for Devyser
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Next-generation sequencing data analysis software is provided.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Devyser
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Devyser
Detailed financials for Devyser
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Devyser Comparisons
Peer comparison for Devyser
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Devyser
Devyser operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, ArcherDX, Stem Cell Technologies, GenScript and Sino Biological, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
Detailed competitors of Devyser
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Devyser
Complete news archive for Devyser
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Devyser
Devyser was founded in 2004 and raised its 1st funding round 17 years after it was founded.
Devyser is headquartered in Stockholm, Sweden.
Devyser is a funded company, having raised a total of $15.48M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Devyser is 132.
Annual revenue of Devyser is $19.66M as on Dec 31, 2024.
Devyser was founded in 2004 in Stockholm, Sweden, and operates in the molecular diagnostics sector. Kits based on next-generation sequencing are offered for BRCA 12 characterization, gene panels targeting familial hypercholesterolemia, cystic fibrosis, thrombophilia, hereditary hemochromatosis, and APOE for Alzheimers risk assessment. Additional products include cardiovascular disease tests, QF-PCR for prenatal aneuploidy, and cytogenetic defect assessments.
Devyser's top competitors include Abcam, Sino Biological and Qiagen.
Devyser offers Devyser BRCA NGS, Devyser Chimerism NGS, Devyser Thalassemia NGS, and Devyser RHD.
Yes, Devyser is publicly traded on OMXSTO under the ticker symbol DVYSR.
Devyser has made 1 acquisition, including SmartSeq.
Devyser has 2 investors. Key investors include Swedbank Robur, and Fjarde AP-fonden.
The ticker symbol of Devyser is DVYSR on OMXSTO.